Skip to main content

Research Repository

Advanced Search

All Outputs (13)

P084 Socioeconomic Outcomes With Ribociclib in Patients With HR+, HER2– Advanced Breast Cancer (ABC) in UK Real-world Settings (2023)
Presentation / Conference Contribution
Hall, P., Howell, S., Venkitaraman, R., Thomson, A., Raja, F., King, J., Michie, C., Khan, S., Brunt, A., Gahir, D., McAdam, K., Cooner, J., & Kane, N. (2023, March). P084 Socioeconomic Outcomes With Ribociclib in Patients With HR+, HER2– Advanced Breast Cancer (ABC) in UK Real-world Settings. Poster presented at 18th St. Gallen International Breast Cancer Conference, Vienna, Austria

OC-0101 First results of FAST-Forward phase 3 RCT nodal substudy: 3-year normal tissue effects (2022)
Presentation / Conference Contribution
Wheatley, D., Haviland, J., Patel, J., Sydenham, M., Alhasso, A., Chan, C., Cleator, S., Coles, C., Donovan, E., Kirby, A., Kirwan, C., Nabi, Z., Sawyer, E., Somaiah, N., Syndikus, I., Venables, K., Yarnold, J., Brunt, A., & Bliss, J. OC-0101 First results of FAST-Forward phase 3 RCT nodal substudy: 3-year normal tissue effects. Presented at ESTRO 2022, 6-10 May 2022, Copenhagen. Onsite in Copenhagen and Online

IMPORT HIGH trial: Dose escalated simultaneous integrated boost radiotherapy in early breast cancer (2021)
Presentation / Conference Contribution
Coles, C., Haviland, J., Kirby, A., Bhattacharya, I., Brunt, A., Chan, C., Donovan, E., Eaton, D., Griffin, C., Hopwood, P., Jefford, M., Lightowlers, S., Rajapakse, C., Sawyer, E., Stones, L., Syndikus, I., Titley, J., Tsang, Y., Twyman, N., Bliss, J., & Yarnold, J. (2021, August). IMPORT HIGH trial: Dose escalated simultaneous integrated boost radiotherapy in early breast cancer. Paper presented at ESTRO 2021, Madrid, Spain & Online

long term follow-up of FoRT: a phase 3 multi-center prospective randomized trial of radiation therapy for follicular and marginal zone lymphoma (2019)
Presentation / Conference Contribution
Hoskin, P., Kirkwood, A., Popova, B., Schofield, O., Brammer, C., Robinson, M., Brunt, M., Krishnaswamy, M., Illidge, T., Gallop-Evans, E., Syndikus, I., & Clifton-Hadley, L. long term follow-up of FoRT: a phase 3 multi-center prospective randomized trial of radiation therapy for follicular and marginal zone lymphoma

Supplement article.

Dose escalated simultaneous integrated boost radiotherapy for women treated by breast conservation surgery for early breast cancer: 3-year adverse effects in the IMPORT HIGH trial (CRUK/06/003) (2019)
Presentation / Conference Contribution
Coles, C., Griffin, C., Kirby, A., Haviland, J., Titley, J., Benstead, K., Brunt, A., Chan, C., Ciurlionis, L., Din, O., Donovan, E., Eaton, D., Harnett, A., Hopwood, P., Jefford, M., Jenkins, P., Lee, C., McCormack, M., Sherwin, L., Syndikus, I., …Yarnold, J. (2018, December). Dose escalated simultaneous integrated boost radiotherapy for women treated by breast conservation surgery for early breast cancer: 3-year adverse effects in the IMPORT HIGH trial (CRUK/06/003). Presented at 2018 San Antonio Breast Cancer Symposium, San Antonio, Texas, USA

Meeting abstract (Abstract GS4-05 from 2018 San Antonio Breast Cancer Symposium; December 4-8, 2018; San Antonio, Texas).

AZD5363 plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (PAKT): A randomised, double-blind, placebo-controlled, phase II trial (2018)
Presentation / Conference Contribution
Schmid, P., Abraham, J., Chan, S., Wheatley, D., Brunt, M., Nemsadze, G., Baird, R., Hee Park, Y., Hall, P., Perren, T., Stein, R. C., László, M., Ferrero, J.-M., Phillips, M., Conibear, J., Sarker, S.-J., Prendergast, A., Cartwright, H., Mousa, K., & Turner, N. C. (2018, June). AZD5363 plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (PAKT): A randomised, double-blind, placebo-controlled, phase II trial. Presented at 2018 ASCO Annual Meeting I, Chicago, IL, USA

Background: The PI3K/AKT signalling pathway is frequently activated in triple-negative breast cancer (TNBC). AZD5363 is a highly-selective, oral, small molecule AKT inhibitor. The PAKT trial investigated the addition of AZD5363 to paclitaxel as 1st-l... Read More about AZD5363 plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (PAKT): A randomised, double-blind, placebo-controlled, phase II trial.

Radioactive Phosphorous (P32) Leukomogenic and Oncogenic Risk Stratification (2018)
Presentation / Conference Contribution
Fullagar, A., Sodhi, L., Pillai, S., & Brunt, A. (2018, April). Radioactive Phosphorous (P32) Leukomogenic and Oncogenic Risk Stratification. Presented at 58th Annual Scientific Meeting of the British-Society-for-Haematology, Liverpool, UK

Meeting abstract

FAST-Forward phase 3 RCT of 1-week hypofractionated breast radiotherapy: 3-year normal tissue effects (2018)
Presentation / Conference Contribution
Brunt, A., Haviland, J., Sydenham, M., Al-hasso, A., Bloomfield, D., Chan, C., Churn, M., Cleator, S., Coles, C., Emson, M., Goodman, A., Griffin, C., Harnett, A., Hopwood, P., Kirby, A., Kirwan, C., Morris, C., Sawyer, E., Somaiah, N., Syndikus, I., …Yarnold, J. FAST-Forward phase 3 RCT of 1-week hypofractionated breast radiotherapy: 3-year normal tissue effects. Presented at ESTRO 37, April 20-24, 2018, Barcelona, Spain

Meeting abstract.

Benefits in early use of eribulin in metastatic breast cancer: A 7-year UHNM experience (2018)
Presentation / Conference Contribution
Yoganayagam, N., Tripathy, A., Exton, S., Rawet, T., Wu, K., Brunt, A., Gahir, D., & Jegannathen, A. (2018, March). Benefits in early use of eribulin in metastatic breast cancer: A 7-year UHNM experience. Poster presented at THE 11TH EUROPEAN BREAST CANCER CONFERENCE, Barcelona, Spain

Meeting abstract from 11th European Breast Cancer Conference (EBCC), Barcelona, Spain, Mar 21-23, 2018.

MANTA - A randomized phase II study of fulvestrant in combination with the dual mTOR inhibitor AZD2014 or everolimus or fulvestrant alone in estrogen receptor-positive advanced or metastatic breast cancer (2017)
Presentation / Conference Contribution
Schmid, P., Zaiss, M., Harper-Wynne, C., Ferreira, M., Dubey, S., Chan, S., Makris, A., Nemsadze, G., Brunt, A., Kuemmel, S., Ruiz Cabrero, I., Perelló, A., Kendall, A., Brown, J., Kristeleit, H., Conibear, J., Saura, C., Grenier, J., Máhr, K., Schenker, M., …Cortes Castan, J. (2017, December). MANTA - A randomized phase II study of fulvestrant in combination with the dual mTOR inhibitor AZD2014 or everolimus or fulvestrant alone in estrogen receptor-positive advanced or metastatic breast cancer. Paper presented at 2017 San Antonio Breast Cancer Symposium, San Antonio, Texas

Background: Resistance to endocrine therapy remains a major clinical challenge with aberrant PI3K/ mTOR pathway activation being one of the main drivers. Randomised clinical trials have demonstrated a substantial benefit of adding everolimus to endoc... Read More about MANTA - A randomized phase II study of fulvestrant in combination with the dual mTOR inhibitor AZD2014 or everolimus or fulvestrant alone in estrogen receptor-positive advanced or metastatic breast cancer.

Partial breast radiotherapy after breast conservation: 5 year outcomes from the IMPORT LOW (CRUK/06/003) phase III trial (2017)
Presentation / Conference Contribution
Coles, C., Griffin, C., Kirby, A., Agrawal, R., Alhasso, A., Bhattacharya, I., Brunt, A., Ciurlionis, L., Chan, H., Donovan, E., Emson, M., Harnett, A., Haviland, J., Hopwood, P., Jefford, M., Kaggwa, R., Sawyer, E., Sybdikus, I., Tsang, Y., Wheatley, D., …Bliss, J. (2017, May). Partial breast radiotherapy after breast conservation: 5 year outcomes from the IMPORT LOW (CRUK/06/003) phase III trial. Presented at ESTRO 36, Vienna, Austria

Conference abstract. Part of special issue:
ESTRO 36, May 5-9, 2017, Vienna, Austria.

Partial breast radiotherapy for women with early breast cancer: First results of local recurrence data for IMPORT LOW (CRUK/06/003) (2016)
Presentation / Conference Contribution
Coles, C., Agrawal, R., Ah-See, M., Algurafi, H., Alhasso, A., Brunt, A., Chan, C., Griffin, C., Harnett, A., Hopwood, P., Kirby, A., Sawyer, E., Syndikus, I., Titley, J., Tsang, Y., Wheatley, D., Wilcox15, M., Yarnold, J., & Bliss, J. (2016, March). Partial breast radiotherapy for women with early breast cancer: First results of local recurrence data for IMPORT LOW (CRUK/06/003). Paper presented at 10th European Breast Cancer Conference (EBCC-10)

Background: IMPORT LOW is a randomised, multi-centre phase III trial testing partial breast radiotherapy (RT) using intensity modulated RT in women with low risk early stage breast cancer, for whom late complications of RT are the dominant hazard rat... Read More about Partial breast radiotherapy for women with early breast cancer: First results of local recurrence data for IMPORT LOW (CRUK/06/003).